Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Role of ZEB1 in angiogenesis and therapeutic potential (Review).

Created on 03 Jul 2026

Authors

Ruoxin Ren, Chunxiao Yan, Yao Xiang, Lin Jin, Fang Cheng, Lijun Zhang

Published in

International journal of molecular medicine. Volume 58. Issue 3. Epub Jul 03, 2026.

Abstract

Zinc finger E‑box binding homeobox 1 (ZEB1), a key transcription factor governing epithelial‑mesenchymal transition, plays indispensable roles in embryonic development, neural differentiation and a wide range of pathological processes. Emerging evidence has revealed that ZEB1 exerts multifaceted and context‑dependent functions in angiogenesis. Under physiological conditions, ZEB1 contributes to the regulation of vascular development and endothelial homeostasis, whereas in pathological settings it promotes aberrant neovascularization through diverse molecular mechanisms. In the present review, the structural characteristics, biological functions and regulatory mechanisms of ZEB1 were systematically summarized, with a particular focus on recent advances regarding its roles in both physiological and pathological angiogenesis. Furthermore, the therapeutic potential of targeting ZEB1 in vascular diseases was discussed and future research directions that may facilitate the development of novel strategies for the prevention and treatment of angiogenesis‑related disorders were highlighted.

PMID:
42396647
Bibliographic data and abstract were imported from PubMed on 03 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement